文献速递神经肿瘤

免疫组化分子亚型标志物与复发脑膜瘤生长行为无相关性

Immunohistochemistry markers of molecular subtype do not correlate with the growth behaviour for recurrent meningiomas - a cohort study.
PubMed 文献 · J Neurooncol · 2025-11-21

结果发现Ki-67、H3K27Me3及S100B、SCGN、ACADL、MCM2等标志物的免疫组化表达均不能预测绝对或相对生长速率。

要点

  • 常规与新型免疫组化标志物均未预测复发脑膜瘤的体积生长速率
  • 原发与复发样本间标志物表达无显著差异(McNemar P均>0.1)
  • 基于免疫组化的分层不推荐用于常规临床实践

核心结论

  • 已确立(Ki-67、H3K27Me3)与新型(S100B、SCGN、ACADL、MCM2)标志物的免疫组化表达均与复发脑膜瘤体积生长无相关性。

研究设计与样本

  • 对首次与第二次切除的配对样本进行六种标志物的免疫组化检测,用椭球公式在系列MRI上计算连续肿瘤体积并按切除后时间校正生长速率。

主要发现

  • 原发与复发样本间免疫组化表达无显著队列差异(McNemar P均>0.1)。
  • 原发样本中17.2%、复发样本中34.5%的肿瘤对≥2种新型标志物呈阳性。
  • 已确立与新型标志物均未预测绝对或相对生长速率(Kruskal–Wallis P均>0.2)。
  • 线性混合效应模型证实标志物表达与纵向肿瘤体积轨迹无关联(P均≥0.1)。

临床怎么用

  • 基于免疫组化的分层因表达模式重叠与分类不一致而受限,不推荐用于常规临床实践。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Established (Ki-67, H3K27Me3) protein biomarkers correlate to clinically aggressive meningioma and can be quickly and easily assessed by immunohistochemistry (IHC). Novel (S100B, SCGN, ACADL, MCM2) markers have also been proposed. The aim of this study was to determine if IHC-based biomarker expression is correlated with volumetric growth rates in recurrent intracranial meningioma following primary resection. METHODS: This was a single-centre retrospective cohort study of adults (≥ 18 years) with surgical resection of recurrent meningioma. Serial tumour volumes were calculated on serial MRI using the ellipsoid formula. Growth rates were calculated and adjusted for time since resection. IHC was performed on paired samples from first and second resections for six markers. Associations between marker expression and tumour growth trajectories were tested using Kruskal–Wallis and linear mixed-effects models. RESULTS: Thirty-one patients were included (mean age 53.1 years, 71% female). No significant cohort differences were found in IHC expression between primary and recurrent samples (all McNemar P > 0.1). Tumours were positive for ≥ 2 novel markers in 17.2% of primary and 34.5% of recurrent samples. Neither established (Ki-67, H3K27Me3) nor novel markers predicted absolute or relative growth rates (all Kruskal–Wallis P > 0.2). Linear mixed-effects models confirmed no association between marker expression and longitudinal tumour volume trajectories (all P ≥ 0.1). CONCLUSION: IHC expression of established or novel markers did not correlate with meningioma volumetric growth. IHC-based stratification is limited by overlapping expression patterns and inconsistent categorisation and is not recommended for routine clinical practice.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Richardson GE, Mustafa MA, Clynch AL, et al. Immunohistochemistry markers of molecular subtype do not correlate with the growth behaviour for recurrent meningiomas - a cohort study. J Neurooncol. 2025. PMID: 41269399. doi:10.1007/s11060-025-05322-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。